I
119THCONGRESS
1
STSESSION H. R. 1143
To amend title XVIII of the Social Security Act to expand coverage of
the in-home administration of intravenous immune globulin under the
Medicare program.
IN THE HOUSE OF REPRESENTATIVES
FEBRUARY7, 2025
Mr. S
MITHof Nebraska (for himself and Mr. GARAMENDI) introduced the fol-
lowing bill; which was referred to the Committee on Energy and Com-
merce, and in addition to the Committee on Ways and Means, for a pe-
riod to be subsequently determined by the Speaker, in each case for con-
sideration of such provisions as fall within the jurisdiction of the com-
mittee concerned
A BILL
To amend title XVIII of the Social Security Act to expand
coverage of the in-home administration of intravenous
immune globulin under the Medicare program.
Be it enacted by the Senate and House of Representa-1
tives of the United States of America in Congress assembled, 2
SECTION 1. SHORT TITLE. 3
This Act may be cited as the ‘‘Medicare IVIG Access 4
Enhancement Act of 2025’’. 5
VerDate Sep 11 2014 18:26 Mar 07, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H1143.IH H1143
ssavage on LAPJG3WLY3PROD with BILLS 2
•HR 1143 IH
SEC. 2. EXPANDING COVERAGE OF THE IN-HOME ADMINIS-1
TRATION OF INTRAVENOUS IMMUNE GLOB-2
ULIN UNDER THE MEDICARE PROGRAM. 3
(a) I
NGENERAL.—Section 1861 of the Social Secu-4
rity Act (42 U.S.C. 1395x) is amended— 5
(1) in subsection (s)(2)(Z), by inserting ‘‘(and, 6
beginning January 1, 2027, for the treatment of 7
chronic inflammatory demyelinating polyneuropathy 8
and multifocal motor neuropathy)’’ after ‘‘primary 9
immune deficiency diseases’’; and 10
(2) in subsection (zz), by inserting ‘‘(or, begin-11
ning January 1, 2027, with diagnosed chronic in-12
flammatory demyelinating polyneuropathy and 13
multifocal motor neuropathy)’’ after ‘‘primary im-14
mune deficiency disease’’. 15
(b) A
UTHORITY FORVARIANCE INPAYMENTS.—Sec-16
tion 1842(o)(8) of the Social Security Act (42 U.S.C. 17
1395u(o)(8)) is amended by inserting ‘‘and may vary de-18
pending on whether such administration is related to 19
treatment of a primary immune deficiency disease or the 20
treatment of chronic inflammatory demyelinating 21
polyneuropathy or multifocal motor neuropathy (as deter-22
mined appropriate by the Secretary through notice and 23
comment rulemaking)’’ after ‘‘of 2012’’. 24
Æ
VerDate Sep 11 2014 18:26 Mar 07, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6301 E:\BILLS\H1143.IH H1143
ssavage on LAPJG3WLY3PROD with BILLS